Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34 + cells

References

• Bearman SI, Shpall EJ, Jones RB et al. High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer. Semin Oncol 1996;23 (1 suppl 2):60–7.
   Google Scholar
• Ross AA, Cooper BW, Lazarus HM et al. Detection and via-bility of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocyto-chemical and clonogenic assay techniques. Blood 1993;82:2605–10.
   PubMed Web of Science ®Google Scholar
• Datta YH, Adams PT, Drobyski WR et al. Sensitive detec-tion of occult breast cancer by the reverse-transcriptase polymerase chain reaction. 7 Clin Oncol 1994;12: 475–82.
   Google Scholar
• Passos-Coelho JL, Ross AA, Moss TJ et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granu-locyte-macrophage colony-stimulating factor. Blood 1995;85: 1138–43.
   PubMed Web of Science ®Google Scholar
• Ross AA, Loudovaris M, Hazelton B et al. Immuno-cytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol 1995;23:1478–83.
   Google Scholar
• Franklin WA, Shpall EJ, Archer P et al. Immuno-cytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 1996;41:1–13.
   PubMed Web of Science ®Google Scholar
• Luppi M, Morselli M, Bandieri E et al Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann Oncol 1996;7:619–24.
   PubMedGoogle Scholar
• Passos-Coelho JL, Ross AA, Kahn DJ et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophos-phamide followed by growth factor. 7 Gun Oncol 1996;14:2569–75.
   PubMed Web of Science ®Google Scholar
• Mapara MY, Korner IJ, Hildebrandt M et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997;89:337–94.
   PubMed Web of Science ®Google Scholar
• Schulze R, Schulze M, Wischnik A et al. Tumor cell conta-mination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant 1997;19:1223–8.
   PubMed Web of Science ®Google Scholar
• Cooper BW, Moss TJ, Ross AA et al. Occult tumor conta-mination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. 7 Clin Oncol 1998; 16:3509–17.
   PubMed Web of Science ®Google Scholar
• Chabannon C, Cornetta K, Lotz J-P et al. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br 7 Cancer 1998;78: 913–21.
   Google Scholar
• Naume B, Borgen E, Nesland JM et al. Increased sensitivity for detection of micrometastases in bone-marrow/periph-eral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int 7 Cancer 1998;78:556–60.
   PubMed Web of Science ®Google Scholar
• Umiel T, Prilutskaya M, Nguyen NH et al. Breast tumor contamination of peripheral blood stem cell harvests: increased sensitivity of detection using immunomagnetic enrichment. .7 Hematother Stem Cell Res 2000;9:895–904.
   PubMedGoogle Scholar
• Vannucchi AM, Bosi A, Glinz S et al. Evaluation of breast tumour cell contamination in the bone marrow and leuka-pheresis collections by RT-PCR for cytokeratin-19 mRNA. Br Haematol1998;103:610–17.
   Google Scholar
• Pedrazzoli P, Battaglia M, Da Prada GA et al Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transplant 1997;20:167–9.
   Google Scholar
• Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow trans-plantation. Lancet 1993;341:85–6.
   PubMed Web of Science ®Google Scholar
• Deisseroth AB, Zu Z, Claxton D et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068–76.
   PubMed Web of Science ®Google Scholar
• Rill DR, Santana VM, Roberts WM et al Direct demonstra-tion that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380–3.
   PubMed Web of Science ®Google Scholar
• Roots-Weifi A, Papadimitriou C, Serve H et al. The effi-ciency of tumor cell purging using immunomagnetic CD34+ cell separation systems. Bone Marrow Transplant 1997;19:1239–46.
   Google Scholar
• Bender JG, Unverzagt K, Walker DE et al. Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autol-ogous stem cell transplantation. Clin Immunol Immunopathol 1994;70:10–18.
   PubMedGoogle Scholar
• Van Epps DE, Bender J, Lee W et al. Harvesting, character-ization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood. Blood Cells 1994;20:411–23.
   Google Scholar
• Marolleau JP, Dal Cortivo L, Mills B et al. Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent. Bone Marrow Transplant 1999;23:819–26.
   Google Scholar
• Moss TJ, Sanders DG, Lasky LC et al. Contamination of peripheral blood stem cell harvests by circulating neurob-lastoma cells. Blood 1990; 76:1879–83.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Ring DB, Tringale F et al Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. 7 Biol Response Mod 1985;4:273–86.
   PubMedGoogle Scholar
• Leslie DS, Johnston WW, Daly L et al Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am 7 Clin Pathol 1990;94:8–13.
   Google Scholar
• Shpall EJ, Bast RC, Joines WT et al Immunomagnetic purg-ing of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991;7:145–51.
   PubMed Web of Science ®Google Scholar
• Moul JW, Lewis DJ, Ross AA et al. Immunohistologic detec-tion of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. Urology 1994;43:68–73.
   Google Scholar
• Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II, or III breast cancer. N Engl .7 Med 2000;342: 525–33.
   Google Scholar
• Okabe T, Takaku F. Diagnostic and therapeutic applications of monoclonal antibodies to small cell carcinoma of the lung. Ypn y Clin Oncol 1986;16:243–52.
   Google Scholar
• Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29–36.
   PubMed Web of Science ®Google Scholar
• McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984;4:137–50.
   PubMed Web of Science ®Google Scholar
• Fogh J, Wright WC, Loveless JD. Absence of HeLa cell con-tamination in 169 cell lines derived from human tumors. Natl Cancer Inst 1977;58: 209–14.
   Google Scholar
• Shpall EJ, Stemmer SM, Hami L et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994;83:3132–7.
   PubMed Web of Science ®Google Scholar
• Passos-Coelho JL, Braine HG, Davis JM et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. 7 Clin Oncol 1995;13: 705–14.
   PubMed Web of Science ®Google Scholar
• Bregni M, De Fabritiis P, Raso V et al. Elimination of clono-genic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conju-gates. Cancer Res 1986;46:1208–13.
   PubMed Web of Science ®Google Scholar
• Demur C, Derocq JM, Poncelet P et al. Effects of an anti HLA-DR immunotoxin on leukaemia cells and hematopoi-etic progenitors. Leuk Res 1989;13:1047–54.
   Google Scholar
• Hohaus S, Pforsich M, Murea S et al. Immunomagnetic selection of CD34+ peripheral blood stem cells for auto-grafting in patients with breast cancer. Br 7 Haematol 1997;97:881–8.
   PubMedGoogle Scholar